PT - JOURNAL ARTICLE AU - Andrew Wolf AU - Enrique Alvarez TI - COVID-19 Vaccination in Patients With Multiple Sclerosis on Disease-Modifying Therapy AID - 10.1212/CPJ.0000000000001088 DP - 2021 Aug 01 TA - Neurology: Clinical Practice PG - 358--361 VI - 11 IP - 4 4099 - http://cp.neurology.org/content/11/4/358.short 4100 - http://cp.neurology.org/content/11/4/358.full AB - The COVID-19 pandemic has resulted in challenges for the practice of neurology. One major concern is how to best manage patients with multiple sclerosis (MS) who are on disease-modifying therapies (DMTs). DMTs frequently have immunosuppressive properties that both increase the risk for COVID-19 and potentially reduce the immunologic response to vaccination in a group already vulnerable to infection due to neurologic deficits. Here, we review early data on COVID-19 outcomes in patients with MS and discuss what is known about vaccine effectiveness in those on anti-CD20 and sphingosine-1-phosphate receptor agents, which are proposed to have attenuating effects based on their mechanisms of action. In addition, we provide recommendations to best use novel COVID-19 vaccines in this population and highlight what information may better inform vaccine strategies in the future.